C12Y 301/06014
N-acetylglucosamine-6-sulfatase
Official title: N-Acetylglucosamine-6-sulfatase (3.1.6.14)
C12Y301/06014 (N-acetylglucosamine-6-sulfatase) appears on 14 US grants and 22 published applications in this corpus.
Search patents in C12Y- Granted patents
- 14
- Published applications
- 22
- Assignees
- 12
- Inventors
- 37
- Latest grant
- 26 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 0 | 2 |
| 2004 | 0 | 0 |
| 2005 | 0 | 1 |
| 2006 | 0 | 2 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 2 |
| 2010 | 0 | 1 |
| 2011 | 1 | 1 |
| 2012 | 2 | 1 |
| 2013 | 1 | 1 |
| 2014 | 0 | 1 |
| 2015 | 1 | 1 |
| 2016 | 1 | 2 |
| 2017 | 0 | 0 |
| 2018 | 3 | 1 |
| 2019 | 0 | 1 |
| 2020 | 1 | 1 |
| 2021 | 1 | 2 |
| 2022 | 1 | 0 |
| 2023 | 0 | 1 |
| 2024 | 0 | 0 |
| 2025 | 1 | 1 |
| 2026 | 1 | 0 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Application of microbial glycosidase as an anti-viral therapeutic, prognostic, and diagnostic26 May 2026US 12,636,353 B2The Regents of the University of California
- Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof7 Jan 2025US 12,188,058 B2Biomarin Pharmaceutical Inc.
- Adenoassociated virus vectors for the treatment of mucopolysaccharidoses24 May 2022US 11,338,046 B2Esteve Pharmaceuticals, S.A.
- Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof2 Mar 2021US 10,934,534 B2Biomarin Pharmaceutical Inc.
- Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof18 Feb 2020US 10,563,183 B2Biomarin Pharmaceutical Inc.
- Circulating biomarker assay for breast cancer prediction23 Oct 2025US 2025/0327112 A1The Board of Regents of the University of Oklahoma
- Application of microbial glycosidase as an anti-viral therapeutic, prognostic, and diagnostic7 Sep 2023US 2023/0277634 A1The Regents of the University of California
- Method and composition for treating hunter syndrome through cerebral lateral ventricle administration15 Jul 2021US 2021/0213109 A1Medigenebio Corporation
- Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof24 Jun 2021US 2021/0189357 A1Biomarin Pharmaceutical Inc.
- Manufacture of Active Highly Phosphorylated Human Lysosomal Sulfatase Enzymes and Uses Thereof11 Jun 2020US 2020/0181590 A1Biomarin Pharmaceutical Inc.
Most cited
By later US patents
- Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof19US 8,128,925 B2Biomarin Pharmaceutical Inc. · 2012
- Delivery of therapeutic agents to the bone4US 7,972,593 B2Saint Louis University · 2011
- Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof4US 8,420,368 B2Biomarin Pharmaceutical Inc. · 2013
- Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof4US 9,200,264 B2Biomarin Pharmaceutical Inc. · 2015
- Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof3US 9,873,867 B2Biomarin Pharmaceutical Inc. · 2018